New drug could keep lung cancer from coming back after surgery
NCT ID NCT06931717
First seen Nov 18, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cemiplimab or be observed without treatment. The main goal is to see if the drug improves disease-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Maggiore della Carità
NOT_YET_RECRUITINGNovara, Italy
Contact Email: •••••@•••••
-
AULSS2 Marca Trevigiana Treviso
NOT_YET_RECRUITINGTreviso, Italy
Contact Email: •••••@•••••
-
Azienda Ospedaliera Universitaria Integrata di Verona
RECRUITINGVerona, Italy
Contact Email: •••••@•••••
-
Azienda ospedaliero-universitaria Senese Siena
NOT_YET_RECRUITINGSiena, Italy
Contact Email: •••••@•••••
-
Beaumont Hospital
RECRUITINGDublin, Ireland
Contact Email: •••••@•••••
-
CHU d'Angers
NOT_YET_RECRUITINGAngers, France
Contact Email: •••••@•••••
-
Centre hospitalier d'Avignon
NOT_YET_RECRUITINGAvignon, France
Contact Email: •••••@•••••
-
Complejo Hospitalario Universitario
RECRUITINGA Coruña, Spain
Contact Email: •••••@•••••
-
Cork University Hospital
NOT_YET_RECRUITINGCork, Ireland
Contact
-
Evangelische Lungenklinik Berlin
NOT_YET_RECRUITINGBuch, Germany
Contact Email: •••••@•••••
-
Fondazione IRCCS Istituto Nazionale dei Tumori
NOT_YET_RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
Fondazione IRCCS Policlinico S. Matteo
RECRUITINGPavia, Italy
Contact Email: •••••@•••••
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Spain
Contact Email: •••••@•••••
-
Hospital Clínico San Cecilio de Granada
RECRUITINGGranada, Spain
Contact Email: •••••@•••••
-
Hospital General Universitario Dr. Balmis de Alicante
RECRUITINGAlicante, Spain
Contact Email: •••••@•••••
-
Hospital General Universitario de Valencia
RECRUITINGValencia, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Cruces
RECRUITINGBarakaldo, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Nuestra Señora de Candelaria
RECRUITINGSanta Cruz de Tenerife, Spain
Contact Email: •••••@•••••
-
Hospital Universitario Vall D'Hebron
RECRUITINGBarcelona, Spain
Contact Email: •••••@•••••
-
Hospital Universitario de Jerez de La Frontera
RECRUITINGJerez de la Frontera, Spain
Contact Email: •••••@•••••
-
Hospital de La Santa Creu I Sant Pau
RECRUITINGBarcelona, Spain
Contact Email: •••••@•••••
-
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
RECRUITINGMeldola, Italy
Contact Email: •••••@•••••
-
Instituto Europeo di Oncologia (IEO)
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
Kantonsspital Winterthur
RECRUITINGWinterthur, Switzerland
Contact Email: •••••@•••••
-
LMU München
RECRUITINGMünchen, Germany
Contact Email: •••••@•••••
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact Email: •••••@•••••
-
North Estonia Medical Centre Foundation
RECRUITINGTalinn, Estonia
Contact Email: •••••@•••••
-
Nuovo Ospedale di Prato Santo Stefano
RECRUITINGPrato, Italy
Contact
-
Pius Hospital, University Medicine Oldenburg
NOT_YET_RECRUITINGOldenburg, Germany
Contact Email: •••••@•••••
-
Ruhrlandklinik Essen
NOT_YET_RECRUITINGEssen, Germany
Contact Email: •••••@•••••
-
St James's Hospital
RECRUITINGDublin, Ireland
Contact Email: •••••@•••••
-
St. Vincent's University Hospital
NOT_YET_RECRUITINGDublin, Ireland
Contact
-
University Hospital Basel
RECRUITINGBasel, Switzerland
Contact Email: •••••@•••••
-
University of Perugia, AO SM Misericorida Perugia
NOT_YET_RECRUITINGPerugia, Italy
Contact Email: •••••@•••••
-
Wien AKH
NOT_YET_RECRUITINGVienna, Austria
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could offer a new option to delay or prevent lung cancer recurrence after surgery without needing chemotherapy.
What could go wrong
This is still being tested—results are not yet known. The drug may cause immune-related side effects, and not all patients may benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.